Meditor Group Ltd Purchases 1,654,100 Shares of Celldex Therapeutics, Inc. (CLDX)

Meditor Group Ltd boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 39.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,800,000 shares of the biopharmaceutical company’s stock after buying an additional 1,654,100 shares during the period. Celldex Therapeutics makes up about 2.2% of Meditor Group Ltd’s portfolio, making the stock its 8th largest position. Meditor Group Ltd owned approximately 4.64% of Celldex Therapeutics worth $14,326,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CLDX. Creative Planning boosted its position in Celldex Therapeutics by 12.2% in the second quarter. Creative Planning now owns 80,136 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 8,716 shares during the period. Goldman Sachs Group Inc. boosted its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 2,453 shares during the period. Credit Suisse AG boosted its position in Celldex Therapeutics by 139.8% in the first quarter. Credit Suisse AG now owns 243,073 shares of the biopharmaceutical company’s stock valued at $877,000 after buying an additional 141,689 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Celldex Therapeutics by 10.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,650 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 6,695 shares during the period. Finally, Level Four Advisory Services LLC bought a new position in Celldex Therapeutics during the first quarter valued at $357,000. 63.88% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celldex Therapeutics, Inc. (CLDX) traded down 1.27% on Friday, reaching $2.33. 726,077 shares of the company’s stock were exchanged. Celldex Therapeutics, Inc. has a one year low of $2.20 and a one year high of $5.02. The firm’s market cap is $299.03 million. The company has a 50 day moving average price of $2.44 and a 200 day moving average price of $2.97.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same quarter in the prior year, the company earned ($0.32) EPS. The business’s revenue was up 175.5% compared to the same quarter last year. Analysts expect that Celldex Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/meditor-group-ltd-buys-1654100-shares-of-celldex-therapeutics-inc-cldx-updated-updated-updated.html.

Several research analysts recently weighed in on the stock. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. Finally, Cowen and Company restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply